GlassScriptPhysician profile
Bradley C Hurliman
NPI 1144357740
$8,084.54
in general payments reported to CMS, 2019-2025
24 companies · $1,530 in 2025
The $1,530 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,650 · 2022: $1,714 · 2023: $1,428 · 2024: $1,762 · 2025: $1,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,253 · Education: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,252.82 |
| Education | $467.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,316.01 | 2021-2025 | |
| Janssen Biotech, INC. | $1,524.16 | 2021-2025 | Tremfya |
| Abbvie INC. | $1,066.38 | 2021-2025 | |
| Genzyme Corporation | $632.97 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $449.43 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $414.10 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $278.25 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $212.60 | 2022-2025 | Bimzelx, Cimzia |
| Sanofi-Aventis U.S. LLC | $178.99 | 2021-2024 | |
| Leo Pharma INC. | $162.70 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $135.18 | 2023-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $117.32 | 2022-2024 | Sotyktu |
| Pfizer INC. | $115.50 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $93.12 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $80.43 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $65.74 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $57.81 | 2021-2022 | |
| Kerecis Limited | $39.31 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Genentech USA, INC. | $34.74 | 2021-2023 | Erivedge |
| Dermavant Sciences, INC. | $31.47 | 2023-2024 | Vtama |
| Allergan, INC. | $22.85 | 2021 | |
| Arcutis Biotherapeutics, INC. | $19.93 | 2023 | |
| Sun Pharmaceutical Industries INC. | $19.04 | 2022 | |
| Verrica Pharmaceuticals INC. | $16.51 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Hurliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.